
Asia Pacific Biosimulation Market Report and Forecast 2024-2032
Description
Asia Pacific Biosimulation Market Report and Forecast 2024-2032
Asia Pacific Biosimulation Market Report and Forecast 2024-2032
Asia Pacific Biosimulation Market Outlook
The global biosimulation market size was valued at USD 3.5 billion in 2023, with Asia Pacific holding a significant market share. The market is driven by the rising advancement in biosimulation technologies. It is expected to grow at a CAGR of 16.90% during the forecast period of 2024-2032, with the values likely to attain USD 14.1 billion by 2032.
Key Takeaways
- The prevalence of at least one chronic disease among the adults and elderly population in India is estimated to be 41.73%. The rising burden of chronic disease fuels the need for effective drugs, thereby impacting market demand.
- In November 2023 , Certara, Inc., introduced Simcyp™ Biopharmaceutics software which is designed to optimize the formulation and development of complex novel and generic small molecule medicines. The rising adoption of such technologically advanced biosimulation platforms in pharmaceutical and biotechnology companies is likely to elevate the Asia Pacific biosimulation market value.
- The market is positively influenced by increasing recognition of biosimulation technologies in improving clinical decisions and patient-specific therapies. In March 2024, a study on gastroesophageal cancer using the Cellworks Biosimulation Platform revealed superior overall survival (OS) and disease-free survival (DFS) predictions for the patients.
Biosimulation can be defined as a computational and mathematical modeling technique that is leveraged to simulate biological processes and systems. Biosimulation models can help predict the behavior of the drugs inside the human body, thereby reducing the time and cost associated with the drug development process. The rapid pharmaceutical expansion in the region is fuelling the demand for such simulation tools for accelerating drug development and is expected to significantly contribute to the Asia Pacific biosimulation market growth.
In Asia Pacific, healthcare demands are witnessing a surge due to an increasing prevalence of chronic diseases and the rising geriatric population in countries such as India and China. The prevalence of at least one chronic disease among the adults and elderly population in India is estimated to be 41.73%. This rising burden of chronic disease reflects the need to develop effective drugs faster. Since biosimulation can expedite the development of targeted therapy and personalized medicine, the market share is expected to grow in the forecast period.
One of the major Asia Pacific biosimulation market trends is the rise in launches of technologically advanced biosimulation software with enhanced capabilities and more accurate modeling. In November 2023 , the global provider of biosimulation software and technology, Certara, Inc., introduced Simcyp™ Biopharmaceutics software which is designed to optimize the formulation and development of complex novel and generic small molecule medicines. It works by maximizing the safety and efficacy of therapies. The platform can help in predicting drug-drug interactions and drug performance in certain populations and can also replace costly clinical bioequivalence studies. The rising adoption of such biosimulation platforms in pharmaceutical and biotechnology companies in the region is likely to elevate the market value.
The Asia Pacific biosimulation market share is positively influenced by increasing recognition of biosimulation technologies in improving clinical decisions and patient-specific therapies. In March 2024, a study on gastroesophageal cancer using the Cellworks Biosimulation Platform (developed by Cellworks Group Inc.) revealed superior overall survival (OS) and disease-free survival (DFS) predictions for the patients. The study further highlighted the pivotal role of biosimulation in personalized therapy selection. Moreover, the increased application of biosimulation is expected to improve patient outcomes and lead to more cost-effective healthcare solutions. Consequently, this is likely to stimulate market demand in the coming years.
Asia Pacific Biosimulation Market Segmentation
Market Breakup by Product Type
- Services
- Software
- Drug Development
- Drug Discovery
- Other Applications
- Subscription Model
- Ownership Model
- Biotechnology and Pharmaceutical Companies
- Research Institutes
- Regulatory Authorities
- Contract Research Organizations
- Japan
- India
- ASEAN
- Australia
- Others
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- LeadInvent Technologies
- Certara Corporation
- Simulations Plus, Inc.
- Dassault Systèmes BIOVIA Corp.
- Insilico Medicine, Inc.
- Physiomics plc
- BioDuro LLC
- Accelrys, Inc.
- Genedata AG
- Rhenovia Pharma
- Biomedical Simulation, Inc.
FAQs
- What is the Asia Pacific biosimulation market forecast outlook for 2024-2032?
- What are the major factors aiding the Asia Pacific biosimulation market demand?
- What are the major Asia Pacific biosimulation trends?
- What is the market segmentation based on the product type?
- What is the market breakup by delivery type?
- What are the major end users of the market?
- What are the applications of the market?
- What is the market segmentation by countries?
- Who are the key players involved in the Asia Pacific biosimulation market?
Meta description
Asia Pacific biosimulation market is poised for growth, driven by the expansion of the global market which was valued at USD 3.5 billion in 2023 and is projected to grow at a CAGR of 16.90% during the forecast period of 2024-2032.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
140 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Asia Pacific Biosimulation Market Overview
- 3.1 Asia Pacific Biosimulation Market Historical Value (2017-2023)
- 3.2 Asia Pacific Biosimulation Market Forecast Value (2024-2032)
- 4 Asia Pacific Biosimulation Market Landscape*
- 4.1 Asia Pacific Biosimulation: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Asia Pacific Biosimulation: Product Landscape
- 4.2.1 Analysis by Product Type
- 4.2.2 Analysis by Application
- 5 Asia Pacific Biosimulation Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Asia Pacific Biosimulation Market Segmentation (2017-2032)
- 6.1 Asia Pacific Biosimulation Market (2017-2032) by Product Type
- 6.1.1 Market Overview
- 6.1.2 Services
- 6.1.3 Software
- 6.2 Asia Pacific Biosimulation Market (2017-2032) by Application
- 6.2.1 Market Overview
- 6.2.2 Drug Development
- 6.2.3 Drug Discovery
- 6.2.4 Other Application
- 6.3 Asia Pacific Biosimulation Market (2017-2032) by Delivery Type
- 6.3.1 Market Overview
- 6.3.2 Subscription Model
- 6.3.3 Ownership Model
- 6.4 Asia Pacific Biosimulation Market (2017-2032) by End User
- 6.4.1 Market Overview
- 6.4.2 Biotechnology & Pharmaceutical Companies
- 6.4.3 Research Institutes
- 6.4.4 Regulatory Authorities
- 6.4.5 Contract Research Organizations
- 6.5 Asia Pacific Biosimulation Market (2017-2032) by Country
- 6.5.1 Market Overview
- 6.5.2 Japan
- 6.5.3 India
- 6.5.4 ASEAN
- 6.5.5 Australia
- 6.5.6 Others
- 7 Japan Biosimulation Market (2017-2032)
- 7.1 Japan Biosimulation Market (2017-2032) by Product Type
- 7.1.1 Market Overview
- 7.1.2 Services
- 7.1.3 Software
- 7.2 Japan Biosimulation Market (2017-2032) by Application
- 7.2.1 Market Overview
- 7.2.2 Drug Development
- 7.2.3 Drug Discovery
- 7.2.4 Other Application
- 7.3 Japan Biosimulation Market (2017-2032) by Delivery Type
- 7.3.1 Market Overview
- 7.3.2 Subscription Model
- 7.3.3 Ownership Model
- 7.4 Japan Biosimulation Market (2017-2032) by End User
- 7.4.1 Market Overview
- 7.4.2 Biotechnology & Pharmaceutical Companies
- 7.4.3 Research Institutes
- 7.4.4 Regulatory Authorities
- 7.4.5 Contract Research Organizations
- 8 India Biosimulation Market (2017-2032)
- 8.1 India Biosimulation Market (2017-2032) by Product Type
- 8.1.1 Market Overview
- 8.1.2 Services
- 8.1.3 Software
- 8.2 India Biosimulation Market (2017-2032) by Application
- 8.2.1 Market Overview
- 8.2.2 Drug Development
- 8.2.3 Drug Discovery
- 8.2.4 Other Application
- 8.3 India Biosimulation Market (2017-2032) by Delivery Type
- 8.3.1 Market Overview
- 8.3.2 Subscription Model
- 8.3.3 Ownership Model
- 8.4 India Biosimulation Market (2017-2032) by End User
- 8.4.1 Market Overview
- 8.4.2 Biotechnology & Pharmaceutical Companies
- 8.4.3 Research Institutes
- 8.4.4 Regulatory Authorities
- 8.4.5 Contract Research Organizations
- 9 ASEAN Biosimulation Market (2017-2032)
- 9.1 ASEAN Biosimulation Market (2017-2032) by Product Type
- 9.1.1 Market Overview
- 9.1.2 Services
- 9.1.3 Software
- 9.2 ASEAN Biosimulation Market (2017-2032) by Application
- 9.2.1 Market Overview
- 9.2.2 Drug Development
- 9.2.3 Drug Discovery
- 9.2.4 Other Application
- 9.3 ASEAN Biosimulation Market (2017-2032) by Delivery Type
- 9.3.1 Market Overview
- 9.3.2 Subscription Model
- 9.3.3 Ownership Model
- 9.4 ASEAN Biosimulation Market (2017-2032) by End User
- 9.4.1 Market Overview
- 9.4.2 Biotechnology & Pharmaceutical Companies
- 9.4.3 Research Institutes
- 9.4.4 Regulatory Authorities
- 9.4.5 Contract Research Organizations
- 10 Australia Biosimulation Market (2017-2032)
- 10.1 Australia Biosimulation Market (2017-2032) by Product Type
- 10.1.1 Market Overview
- 10.1.2 Services
- 10.1.3 Software
- 10.2 Australia Biosimulation Market (2017-2032) by Application
- 10.2.1 Market Overview
- 10.2.2 Drug Development
- 10.2.3 Drug Discovery
- 10.2.4 Other Application
- 10.3 Australia Biosimulation Market (2017-2032) by Delivery Type
- 10.3.1 Market Overview
- 10.3.2 Subscription Model
- 10.3.3 Ownership Model
- 10.4 Australia Biosimulation Market (2017-2032) by End User
- 10.4.1 Market Overview
- 10.4.2 Biotechnology & Pharmaceutical Companies
- 10.4.3 Research Institutes
- 10.4.4 Regulatory Authorities
- 10.4.5 Contract Research Organizations
- 11 Regulatory Framework
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication Year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
- 13.1 Analysis by Year
- 13.2 Analysis by Amount Awarded
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Grant Application
- 13.5 Analysis by Funding Institute
- 13.6 Analysis by Departments
- 13.7 Analysis by Recipient Organization
- 14 Funding and Investment Analysis
- 14.1 Analysis by Funding Instances
- 14.2 Analysis by Type of Funding
- 14.3 Analysis by Funding Amount
- 14.4 Analysis by Leading Players
- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
- 15.1 Analysis by Partnership Instances
- 15.2 Analysis by Type of Partnership
- 15.3 Analysis by Leading Players
- 15.4 Analysis by Geography
- 16 Supplier Landscape
- 16.1 Market Share by Top 5 Companies
- 16.2 LeadInvent Technologies
- 16.2.1 Financial Analysis
- 16.2.2 Product Portfolio
- 16.2.3 Demographic Reach and Achievements
- 16.2.4 Mergers and Acquisitions
- 16.2.5 Certifications
- 16.3 Certara Corporation
- 16.3.1 Financial Analysis
- 16.3.2 Product Portfolio
- 16.3.3 Demographic Reach and Achievements
- 16.3.4 Mergers and Acquisitions
- 16.3.5 Certifications
- 16.4 Simulations Plus, Inc.
- 16.4.1 Financial Analysis
- 16.4.2 Product Portfolio
- 16.4.3 Demographic Reach and Achievements
- 16.4.4 Mergers and Acquisitions
- 16.4.5 Certifications
- 16.5 Dassault Systèmes BIOVIA Corp.
- 16.5.1 Financial Analysis
- 16.5.2 Product Portfolio
- 16.5.3 Demographic Reach and Achievements
- 16.5.4 Mergers and Acquisitions
- 16.5.5 Certifications
- 16.6 Insilico Medicine, Inc.
- 16.6.1 Financial Analysis
- 16.6.2 Product Portfolio
- 16.6.3 Demographic Reach and Achievements
- 16.6.4 Mergers and Acquisitions
- 16.6.5 Certifications
- 16.7 Physiomics plc
- 16.7.1 Financial Analysis
- 16.7.2 Product Portfolio
- 16.7.3 Demographic Reach and Achievements
- 16.7.4 Mergers and Acquisitions
- 16.7.5 Certifications
- 16.8 BioDuro LLC
- 16.8.1 Financial Analysis
- 16.8.2 Product Portfolio
- 16.8.3 Demographic Reach and Achievements
- 16.8.4 Mergers and Acquisitions
- 16.8.5 Certifications
- 16.9 Accelrys, Inc.
- 16.9.1 Financial Analysis
- 16.9.2 Product Portfolio
- 16.9.3 Demographic Reach and Achievements
- 16.9.4 Mergers and Acquisitions
- 16.9.5 Certifications
- 16.10 Genedata AG
- 16.10.1 Financial Analysis
- 16.10.2 Product Portfolio
- 16.10.3 Demographic
- 16.10.4 Mergers and Acquisitions
- 16.10.5 Certifications
- 16.11 Rhenovia Pharma
- 16.11.1 Financial Analysis
- 16.11.2 Product Portfolio
- 16.11.3 Demographic Reach and Achievements
- 16.11.4 Mergers and Acquisitions
- 16.11.5 Certifications
- 16.12 Biomedical Simulation, Inc.
- 16.12.1 Financial Analysis
- 16.12.2 Product Portfolio
- 16.12.3 Demographic Reach and Achievements
- 16.12.4 Mergers and Acquisitions
- 16.12.5 Certifications
- 17 Asia Pacific Biosimulation Market – Distribution Model (Additional Insight)
- 17.1 Overview
- 17.2 Potential Distributors
- 17.3 Key Parameters for Distribution Partner Assessment
- 18 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 19 Company Competitiveness Analysis (Additional Insight)
- 19.1 Very Small Companies
- 19.2 Small Companies
- 19.3 Mid-Sized Companies
- 19.4 Large Companies
- 19.5 Very Large Companies
- 20 Payment Methods (Additional Insight)
- 20.1 Government Funded
- 20.2 Private Insurance
- 20.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.